Human Bocavirus Capsid Messenger RNA Detection in Children With Pneumonia

Salais, Robert; Ampofo, Krow; Tardif, Keith D.; Simmon, Keith E.; Hymas, Weston; Flygare, Steven; Kennedy, Brett; Blaschke, Anne J.; Eilbeck, Karen; Yandell, Mark; McCullers, Jonathan A.; Williams, Derek J.; Edwards, Kathryn M.; Arnold, Sandra R.; Bramley, Anna M.; Jain, Seema; Pavia, Andrew T.

doi:10.1093/infdis/jix352

Cited by 25 publications

(23 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detection rates of 15% for HBoV1 DNA, 2.7% for mRNA and 3.0% for high DNA load (> 10 6 copies/mL) in children with RTI are in agreement with previous reports in the literature [7,9,10,14,15]. Taken together, the results suggest that only about a fifth of the children with HBoV1 DNA in the nasopharynx has an acute HBoV1 infection.…”

Section: Discussionsupporting

confidence: 91%

“…The widely used qualitative HBoV1 DNA PCRs yield results of low clinical specificity and very low PPV [1,2,6,7,14]. We confirmed this.…”

Section: Discussionsupporting

confidence: 82%

“…mRNA is a marker of actively transcribing virus during an ongoing infection, and a rapidly declining DNA load is the normal outcome after an acute infection. The HBoV1 mRNA test has performed well in studies, providing support for its use as reference [6,7,9,10]. Furthermore, a high DNA load (> 10 4 or > 10 6 copies/mL) in nasopharyngeal secretions has been shown to be a better diagnostic criterion than mere DNA detection by endpoint PCR [8,[14][15][16].…”

Section: Discussionmentioning

confidence: 94%

“…The diagnosis of HBoV1 infections has traditionally been based on qualitative PCRs detecting viral DNA. Recent studies have however shown that the clinical value of this approach is low due to persistence of HBoV1 DNA in the airways, leading to frequent detection of low concentrations in healthy children [6][7][8]. Clinical specificity of HBoV1 mRNA detection has been shown to be superior to that of HBoV1 DNA detection [6,9,10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children

Kols

Aatola²,

Peltola

et al. 2019

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

“…The widely used qualitative HBoV1 DNA PCRs yield results of low clinical specificity and very low PPV [1,2,6,7,14]. We confirmed this.…”

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children

Kols

Aatola²,

Peltola

et al. 2019

Journal of Clinical Virology

View full text Add to dashboard Cite

“…A recent case-control study shown similar rates of HBoV genomic DNA detection in symptomatic (10.4%) and asymptomatic children (7.5%), suggesting that its detection did not imply necessarily pathogenicity in the respiratory tract by itself. This study found that HBoV capsid mRNA detection could differentiate acute infections from prolonged shedding [32]. Still, in our series HBoV detection was a rare phenomenon, representing 3% of all CARVs.…”

Section: Discussionmentioning

confidence: 43%

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study

Piñana

Madrid

Pérez³

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Epidemiologic data about coronaviruses (CoVs) and human bocavirus (HBoV) in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are scarce. We conducted a prospective longitudinal study on respiratory viral infections (RVIs) in allo-HSCT recipients with respiratory symptoms from December 2013 until June 2016. Respiratory virus in upper and/or lower respiratory tract (URT and LRT) specimens were tested using Luminex xTAG RVP Fast v1 assay. Seventy-nine consecutive allo-HSCT recipients developed a total of 192 virologically documented RVI episodes over 30 months. The median follow-up after RVI was 388 days (range, 5 to 923). CoV or HBoV was detected in 27 of 192 episodes (14%); 18 of 79 recipients (23%) developed a total of 21 CoV RVI episodes, whereas 6 recipients (8%) had 1 HBoV RVI episode each. Fourteen CoV RVI episodes were limited to the URT, whereas 7 affected the LRT. Co-pathogens were detected in 8 (38%) CoV cases. Type OC43 CoV was the dominant type (48%) followed by NL63 (24%), KHU1 (19%), and 229E (9%); the CoV hospitalization rate was 19%, whereas mortality was 5% (1 patient without any other microbiologic documentation). Among the 6 recipients with HBoV (3%), only 1 had LRT involvement and no one died from respiratory failure. In 5 cases (83%) HBoV was detected along with other viral co-pathogens. CoV RVIs are common after allo-HSCT, and in a significant proportion of cases CoV progressed to LRT and showed moderate to severe clinical features. In contrast, HBoV RVIs were rare and mostly presented in the context of co-infections.

show abstract

Development of RPA‐Cas12a‐fluorescence assay for rapid and reliable detection of human bocavirus 1

Qian

Wang

et al. 2023

Anim Models and Exp Med

View full text Add to dashboard Cite

Human bocavirus (HBoV) 1 is considered an important pathogen that mainly affects infants aged 6–24 months, but preventing viral transmission in resource‐limited regions through rapid and affordable on‐site diagnosis of individuals with early infection of HBoV1 remains somewhat challenging. Herein, we present a novel faster, lower cost, reliable method for the detection of HBoV1, which integrates a recombinase polymerase amplification (RPA) assay with the CRISPR/Cas12a system, designated the RPA‐Cas12a‐fluorescence assay. The RPA‐Cas12a‐fluorescence system can specifically detect target gene levels as low as 0.5 copies of HBoV1 plasmid DNA per microliter within 40 min at 37°C without the need for sophisticated instruments. The method also demonstrates excellent specificity without cross‐reactivity to non‐target pathogens. Furthermore, the method was appraised using 28 clinical samples, and displayed high accuracy with positive and negative predictive agreement of 90.9% and 100%, respectively. Therefore, our proposed rapid and sensitive HBoV1 detection method, the RPA‐Cas12a‐fluorescence assay, shows promising potential for early on‐site diagnosis of HBoV1 infection in the fields of public health and health care. The established RPA‐Cas12a‐fluorescence assay is rapid and reliable method for human bocavirus 1 detection. The RPA‐Cas12a‐fluorescence assay can be completed within 40 min with robust specificity and sensitivity of 0.5 copies/μl.

show abstract

Human Bocavirus Capsid Messenger RNA Detection in Children With Pneumonia

Abstract: Detection of HBoV mRNA but not DNA was associated with CAP, supporting a pathogenic role for HBoV in CAP. HBoV mRNA could be a useful target for diagnostic testing.

Cited by 25 publications

References 50 publications

Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children

Comparison of phenotypic and genotypic diagnosis of acute human bocavirus 1 infection in children

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study

Development of RPA‐Cas12a‐fluorescence assay for rapid and reliable detection of human bocavirus 1

Contact Info

Product

Resources

About